Title | Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study. |
Publication Type | Journal Article |
Year of Publication | 2014 |
Authors | Shores, MM, Biggs, ML, Arnold, AM, Smith, NL, Longstreth, WT, Kizer, JR, Hirsch, CH, Cappola, AR, Matsumoto, AM |
Journal | J Clin Endocrinol Metab |
Volume | 99 |
Issue | 6 |
Pagination | 2061-8 |
Date Published | 2014 Jun |
ISSN | 1945-7197 |
Keywords | Aged, Aged, 80 and over, Cardiovascular Diseases, Cause of Death, Dihydrotestosterone, Humans, Incidence, Longitudinal Studies, Male, Mortality, Residence Characteristics, Risk Factors, Testosterone |
Abstract | <p><b>CONTEXT: </b>Low testosterone (T) is associated with prevalent cardiovascular disease (CVD) and mortality. DHT, a more potent androgen, may also be associated with CVD and mortality, but few studies have examined this.</p><p><b>OBJECTIVE: </b>The study objective was to examine whether T and DHT are risk factors for incident CVD and mortality.</p><p><b>DESIGN: </b>In a longitudinal cohort study, we evaluated whether total T, calculated free T (cFT), DHT, and calculated free DHT were associated with incident CVD and mortality in men in the Cardiovascular Health Study (mean age 76, range 66-97 years) who were free of CVD at the time of blood collection.</p><p><b>MAIN OUTCOME: </b>The main outcomes were incident CVD and all-cause mortality.</p><p><b>RESULTS: </b>Among 1032 men followed for a median of 9 years, 436 incident CVD events and 777 deaths occurred. In models adjusted for cardiovascular risk factors, total T and cFT were not associated with incident CVD or all-cause mortality, whereas DHT and calculated free DHT had curvilinear associations with incident CVD (P < .002 and P = .04, respectively) and all-cause mortality (P < .001 for both).</p><p><b>CONCLUSIONS: </b>In a cohort of elderly men, DHT and calculated free DHT were associated with incident CVD and all-cause mortality. Further studies are needed to confirm these results and to clarify the underlying physiologic mechanisms.</p> |
DOI | 10.1210/jc.2013-3576 |
Alternate Journal | J. Clin. Endocrinol. Metab. |
PubMed ID | 24628549 |
PubMed Central ID | PMC4037728 |
Grant List | 1R01HL091952 / HL / NHLBI NIH HHS / United States U01 HL080295 / HL / NHLBI NIH HHS / United States N01HC55222 / HL / NHLBI NIH HHS / United States N01HC85086 / HL / NHLBI NIH HHS / United States HHSN268201200036C / HL / NHLBI NIH HHS / United States R01 HL080295 / HL / NHLBI NIH HHS / United States N01HC85082 / HL / NHLBI NIH HHS / United States N01HC85083 / HL / NHLBI NIH HHS / United States HL080295 / HL / NHLBI NIH HHS / United States R01 HL091952 / HL / NHLBI NIH HHS / United States AG-023629 / AG / NIA NIH HHS / United States N01HC85079 / HL / NHLBI NIH HHS / United States R01 AG023629 / AG / NIA NIH HHS / United States N01HC85080 / HL / NHLBI NIH HHS / United States R56 AG023629 / AG / NIA NIH HHS / United States N01HC85081 / HL / NHLBI NIH HHS / United States |